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Abstract
Previously, we identified the transcription factor CUX1 as an important modulator of invasion and resistance to
apoptosis. Expression profiles suggested that CUX1 regulates a complex transcriptional program mediating tumor
progression. We aimed to identify functionally relevant targets of CUX1 by using RNA interference (RNAi)–based
loss-of-function screens. Therefore, we generated an RNAi library containing putative transcriptional targets of
CUX1 identified by microarrays and performed cell viability screens. Using this approach, several CUX1 targets
with effect on tumor cell viability were identified, including the glutamate receptor GRIA3, which was validated
in detail for its effects on proliferation, apoptosis, and cell migration using RNAi knock-down and overexpression
strategies in vitro, as well as xenograft models in vivo. The expression of GRIA3 was evaluated in human pancreatic
cancer tissues. We found that knock-down of GRIA3 significantly reduced proliferation and migration and en-
hanced apoptosis. In contrast, overexpression of GRIA3 significantly reduced apoptosis and enhanced both
proliferation and tumor cell migration. GRIA3 could be confirmed as a downstream effector of CUX1 and was
expressed in pancreatic cancer tissues. In vivo, GRIA3 significantly enhanced the growth of subcutaneous
xenografts. Inhibitors of glutamate receptors such as GYKI52466 and SYM2206 significantly decreased survival
of pancreatic cancer cells, suggesting the presence of glutamate signaling in pancreatic cancer. In conclusion, GRIA3
plays a role as a mediator of tumor progression in pancreatic cancer downstream CUX1. To our knowledge, this
is the first report to identify a glutamate receptor as a modulator of tumor progression in a solid cancer outside
the brain.
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Introduction
Pancreatic cancer carries the most dismal prognosis of all solid tu-
mors, with a 5-year survival rate of less than 5% and a median sur-
vival of less than 6 months [1]. Most patients are diagnosed with
pancreatic cancer at advanced stages of the disease. However, even
after curative surgery at early stages, local recurrence occurs in many
patients. Many reports demonstrate that perineural invasion, that is,
spread of cancer cells in the perineural space, is one of the determi-
nants of local recurrence and one of the most significant poor prog-
nostic factors [2,3]. The molecular basis for this propensity to invade
perineurally is largely unknown. Once local recurrence or metastatic
stage has developed, pancreatic cancer is highly resistant to any thera-
peutic regimen tested so far [4].
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate; siRNA,
small interfering RNA; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand
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The transcription factor CUX1, also known as CDP (CCAAT dis-
placement protein) or CUTL1, belongs to a evolutionarily conserved
family of homeobox transcription factors involved in the regulation
of cell proliferation, embryonic development, and cell differentiation
[5,6]. CUX1 is expressed as multiple isoforms and is cleaved by pro-
teases such as cathepsin L in transcriptionally more active C-terminal
fragments [7].
Transcriptional activation of CUX1 leads to increased proliferation
in various cell systems [8,9]. Previously, we have shown that CUX1
stimulates tumor cell motility and invasion in vitro and in vivo by or-
chestrating a complex transcriptional program [10–13]. Furthermore,
we recently identified CUX1 as a potent inhibitor of apoptosis and sur-
vival factor in pancreatic cancer [14]. The important role of CUX1 in
promoting cell tumor progression is underlined by the fact that CUX1
expression is strongly associated with a less differentiated phenotype
and decreased survival in patients with breast cancer [10,15]. Recently,
these data could be corroborated by other reports that described the
development of mammary tumors in a CUX1-transgenic mouse model
[16] and an important role of CUX1 in the regulation of genes asso-
ciated with metastasis and epithelial-mesenchymal transition [17].
To search for downstream effectors transcriptionally regulated by
CUX1, we previously performed whole-genome expression profiling
experiments [10]. By using this approach, we identified a list of 41
putative target genes regulated by CUX1 [10]. To functionally screen
these targets for effects on survival, we generated a custom RNA in-
terference (RNAi) library containing these 41 genes. The sequential
combination of transcriptional profiles and loss-of-function screens
identified several functionally relevant CUX1 targets. Interestingly,
GRIA3, a subunit of ionotropic glutamate receptors, also known as
α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA) recep-
tors (AMPARs), which have been mainly described in the central
nervous system (CNS), was among these hits. GRIA3 is one of four
subunits of the AMPAR, which combine to form heterotetramers [18].
In the current study, we characterized GRIA3 as an important medi-
ator of tumor progression in pancreatic cancer in vitro and in vivo.
Materials and Methods
Materials and Cell Lines
PANC1 and HT1080 cell lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA). The PaTu-8988t cell
line was received from the German Collection of Cell Lines (DSMZ;
Braunschweig, Germany). Cells were maintained inDulbecco modified
Eagle medium (GIBCO, Invitrogen, Grand Island, NY) supplemented
with 10% fetal calf serum (GIBCO), 100 μg/ml streptomycin, and
100 U/ml penicillin. All cells were cultured in a humidified atmosphere
containing 5% CO2 at 37°C.
Recombinant human tumor necrosis factor (TNF)–related apoptosis-
inducing ligand (TRAIL/TNFSF10) was obtained from R&D Sys-
tems (Minneapolis, MN) and used at a concentration of 100 ng/ml
for PANC1 and 75 ng/ml for PaTu-8988t. The AMPAR inhibitors
SYM2206 and GYKI52466 were purchased from Tocris Bioscience
(Bristol, UK).
RNAi Library
A total of 41 genes were selected as putative CUX1 targets, which
were differentially expressed in a genome-wide microarray profile for
CUX1 target genes published previously [10]. Three small interfering
RNA (siRNA) duplexes from Ambion (Austin, TX) with independent
silencing sequences were used for each gene. For siRNA transfection,
HT1080 cells were seeded onto a 96-well plate. After 24 hours, cells
were transfected with siRNA using siLentFect Lipid Reagent (BioRad,
Munich, Germany) following the manufacturer’s instructions. Forty-
eight hours later, cell viability was measured using CellTiter-Glo
luminescent assay (Promega, Madison, WI) according to the manufac-
turer’s instructions.
Plasmids and siRNA
Myc-tagged full-length human p180 CUX1-pMX (180 kDa) and
the transcriptionally active C-terminal CUX1-pXJ (75 kDa) were kind
gifts from A. Nepveu (McGill University, Montreal, Quebec, Canada).
GRIA3-pcDNA3.1 (flip splicing variant) was kindly provided by
L. Niu (State University of New York, New York, NY). For stable ex-
pression of CUX1, C-terminal CUX1 was cloned into pcDNA3-neo.
All plasmids were transfected using TransFast Transfection Reagent
(Promega). Stable clones were selected with neomycin (1 mg/ml; PAA
Laboratories, Pasching, Austria).
All siRNA experiments were performed using two independent silenc-
ing sequences (hCUX1_1, hCUX1_2, hGRIA3_1, and hGRIA3_2),
which were purchased from Ambion, and these are available on request.
All cells were transfected with siRNA using siLentFect (BioRad) ac-
cording to the manufacturer’s instructions. As nonsilencing control,
control siRNA (Ambion) was used.
Quantitative Real-time Polymerase Chain Reaction Analysis
RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). First-strand complementary DNA was synthesized using
Oligo(dt)-Primers (Ambion) and Omniscript RT Kit (Qiagen). Quan-
titative reverse transcription–polymerase chain reaction (RT-PCR)
analysis was performed using 7500 Fast Real-time PCR and the SYBR
Green PCR Master Mix Kit (Applied Biosystems, Wellesley, MA) ac-
cording to the manufacturer’s instructions. Primers were designed with
the PrimerExpress program (Applied Biosystems), and these are available
on request. Primers for the ribosomal protein RPLP0 (NM_001002)
were used as internal standard.
Immunoblot Analysis
Immunoblots were performed as described before [11] and probed
with primary antibodies againstCUX1 [11],GRIA3 (Millipore, Billerica,
MA), poly (ADP-ribose) polymerase (PARP) (Cell Signaling Technology,
Beverly, MA), and β-actin (Sigma-Aldrich, St Louis, MO).
Proliferation and Viability Assays
[3H]thymidine incorporation was performed as described previously
[11], and Bromodeoxyuridine (BrdU) incorporation was measured by
using the colorimetric BrdU Cell Proliferation ELISA (Roche Diag-
nostics, Indianapolis, IN) according to the manufacturer’s instructions.
For proliferation assays with cells transiently transfected with expres-
sion plasmids, the number of transfected cells was counted under the
microscope. To selectively assess the proliferation of transiently trans-
fected cells, cotransfections with LacZ plasmid were performed. After
24 hours, cells were fixed and stained using X-Gal stain (Sigma). Pro-
liferation was calculated by counting blue-stained cells.
Cell viability was determined by using the CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega) or the MTT Cell Proliferation Kit
(Roche Diagnostics, Mannheim, Germany) according to the manufac-
turer’s instructions.
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FACS
FACS analysis was performed as described previously [19]. In brief,
cells were stained with propidium iodide after RNase treatment and
analyzed in a FACScan flow cytometer (Becton Dickinson, Heidelberg,
Germany). Cell cycle was analyzed using the FlowJo software (Tree Star,
Ashland, OR).
Two-Chamber Migration Assays
Two-chamber Boyden migration assays were performed as described
previously [10]. The number of migrated cells was measured by the
CellTiter-Glo Luminescent Cell Viability Assay (Promega) and nor-
malized to the total number of proliferating cells in a neighbor well.
Apoptosis Assays
For quantification of histone-associated DNA fragments, we used
the Cell Death Detection ElisaPLUS (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions. Activities of
caspase-3 and -7 were measured using a luminogenic caspase-3/7 sub-
strate in the Caspase-Glo 3/7 assay (Promega) according to the man-
ufacturer’s instructions. PARP cleavage was assessed using a specific
antibody detecting cleaved PARP (Cell Signaling Technology).
nu/nu Mice Xenografts
Female nu/nu mice were injected subcutaneously with 106 PANC1
cells/0.1 ml of phosphate-buffered saline. Five mice per group were in-
jected, and two clones each of cells stably transfected with GRIA3flip-
pcDNA3 or empty pcDNA3 vector were used. Tumor growth was
determined by regular measurements of the three diameters from
day 14 until sacrifice at day 46 after tumor cell inoculation.
Immunohistochemistry
For immunohistochemical analysis, an independent set of 17 hu-
man pancreatic adenocarcinoma tissues was provided by the Institute
of Pathology of the University of Marburg according to the guidelines
of the local ethics committee. Immunohistochemical analysis was per-
formed by using a rabbit polyclonal anti-GRIA2/3 (1:50; Abcam,
Cambridge, UK), as described previously [10].
Statistical Analysis
For the in vitro experiments, statistical analyses were performed
using the double-sided unpaired Student’s t test after Bonferroni cor-
rection for multiple testing, where appropriate. Differences in tumor
growth in the mouse xenografts were analyzed using paired t test/
Wilcoxon matched pairs test.
Results
Loss-of-Function Screen of CUX1 Targets
Previously, we performed genome-wide expression profiles inNIH3T3
cells with or without stable knock-down of CUX1 by RNAi to identify
transcriptional targets of CUX1 mediating its effects on tumor progres-
sion [10]. Among the lists of putative target genes resulting from these
profiling experiments, we aimed to perform unbiased loss-of-function
screens for functionally relevant CUX1 targets affecting cell survival.
For this purpose, we designed a custom RNAi library containing 41
genes identified by microarray analysis. A detailed list of these genes is
available in Table W1. Given the strong effect of CUX1 on cell survival
[14], we performed cell viability assays in a 96-well plate format as read-
out. As the cellular system,we usedHT1080 cells that we had previously
used to validate our microarray results [10]. To confirm a sufficient
knock-down efficacy in our experimental setting, we randomly selected
five genes for all of which we could demonstrate a knock-down of more
than 70% on RNA level 48 hours after transfection of siRNA oligo-
nucleotides (Figure W1).
The loss-of-function screen led to a significant decrease in cell via-
bility in 7 of the 41 genes (Table 1). Significance was defined as change
in viability greater than 25% after 48 hours in at least two of three
silencing sequences. The seven hits comprised genes involved in di-
verse cellular functions such as cell-cell adhesion (GJA1 and PVRL3),
deacetylation (SIRT2), glutamate signaling (GRIA3), and transcrip-
tional regulation (ARNTL).
As a first step in our validation process, we aimed to confirm the
screen data in several independent cell lines. Given our previous ob-
servations that CUX1 is highly expressed and promoting tumor pro-
gression in pancreatic cancer [10,13,14], we focused on pancreatic
cancer cells to validate the screen hits. Among the seven hits, we were
interested in genes that either were upregulated by CUX1 and whose
knock-down reduced cell viability or in genes that were downregu-
lated by CUX1 and whose knock-down enhanced cell viability. These
genes are likely to represent targets mediating CUX1-induced tumor
progression. First, we performed real-time PCR experiments with the
pancreatic cancer cell lines PaTu-8988t and PANC1. Transient knock-
down of CUX1 in both cells confirmed expression and up-regulation
or down-regulation by CUX1 on the messenger RNA (mRNA) level
in accordance with the previous microarray data for five of seven genes
(SIRT2, GJA1, GRIA3, PVRL3, and FMOD; see Figures W2 [PANC1]
andW3 [PaTu-8988t]). Four of these five genes (SIRT2,GJA1,GRIA3,
and PVRL3), whose knock-down reduced cell viability, were up-
regulated by CUX1, whereas one gene (FMOD), whose knock-down
Table 1. RNAi Target Genes.
Gene Symbol Relative Viability
(siRNA Sequence 1)
Relative Viability
(siRNA Sequence 2)
Relative Viability
(siRNA Sequence 3)
Mean Viability
Relative to Control
Significance
Criteria
Regulation by CUX1 in
NIH3T3 (Microarray)
SIRT2 0.60 0.64 0.76 0.67 * Up
GJA1 0.77 0.65 0.59 0.67 * Up
GRIA3 0.71 0.57 0.88 0.72 * Up
PVRL3 0.68 0.57 0.97 0.74 * Up
CXCL12 0.45 0.95 0.42 0.61 * Down
FMOD 0.88 1.46 1.25 1.20 * Down
ARNTL 1.47 1.65 1.13 1.42 * Up
List of the 7 of 41 genes fulfilling significance criteria in the RNAi screen. Cell viability relative to the mean viability of 11 nonsilencing control sequences, as determined by CellTiter-Glo assays, is shown
as mean and separately for silencing sequences 1 to 3. The genes used for the screen were previously identified as regulated by CUX1 in a microarray approach [10]. Up-regulation or down-regulation of
the genes by CUX1 in the previous microarray experiment is shown in the right column.
Significance was defined as change in viability greater than 25% after 48 hours in at least two or three silencing sequences and marked with an asterisk.
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enhanced cell viability, was downregulated by CUX1 in all the ex-
amined cell lines. This indicates that these target genes identified by
the combinatorial approach of transcriptional profiling and subsequent
loss-of-function screening might be involved in mediating CUX1-
induced tumor cell survival.
Among these screen results, GRIA3 caught our particular interest
for further validation in the current study. GRIA3 is known as subunit
of the ionotropic AMPAR in the CNS. To our knowledge, no data
exist so far on the role of GRIA subunits in tumors outside the brain.
GRIA3 Is Regulated by CUX1
First, we verified that GRIA3 is transcriptionally regulated by CUX1.
On the RNA level, we performed quantitative RT-PCR of PaTu-8988t
and PANC1 cells with or without knock-down of CUX1 by siRNA.
Knock-down of CUX1 significantly reduced GRIA3 mRNA in both
cell lines (Figure 1A). Moreover, we examined the effect of transiently
overexpressed CUX1 on GRIA3 mRNA expression. Because full-
length CUX1 is endogenously cleaved by cathepsin L resulting in a
transcriptionally active C-terminal fragment [7], we used a transcrip-
tionally active C-terminal CUX1 p75 plasmid for transfection exper-
iments. Transient overexpression of CUX1 resulted in significant
up-regulation of GRIA3 mRNA (Figure 1B). To confirm the regula-
tion of GRIA3 by CUX1 on the protein level, we performed Western
blots. In analogy to the CUX1 effects seen on the RNA level, knock-
down of CUX1 resulted in decreased GRIA3 protein levels (Figure 1C),
whereas CUX1 overexpression increased GRIA3 levels in both cell lines
(Figure 1D).
To further confirm the regulation of GRIA3 by CUX1, we analyzed
stable PANC1 clones expressing the transcriptionally active C-terminal
CUX1 fragment [5] at different expression levels. In these clones,
GRIA3 protein (Figure W4A) and mRNA (Figure W4B) expressions
were positively correlated with CUX1 levels, further corroborating the
regulation of GRIA3 by CUX1.
GRIA3 Enhances Proliferation
On the basis of our screen results demonstrating the effect of GRIA3
on cell viability, we first aimed to characterize its effects on proliferation
in more detail.
Proliferation was analyzed after transient knock-down and over-
expression of GRIA3 in PANC1 and PaTu-8988t cells. Knock-down
of GRIA3 resulted in significantly reduced [3H]thymidine incorpora-
tion in both cell lines (Figure 2A). This was associated with a marked
decrease in S phase and increase in G1 phase, as assessed by FACS cell
cycle analysis in PANC1 cells (Figure 2B). In contrast, transient over-
expression of GRIA3 led to a significant increase in cell number, which
was determined by counting X-Gal–positive cells after cotransfection
of both LacZ and GRIA3 (Figure 2C). To investigate the long-term
effects of GRIA3 on proliferation, we generated stable PANC1 clones.
Figure 1. GRIA3 is upregulated by CUX1. (A) Knock-down of CUX1 decreases GRIA3 mRNA. PaTu-8988t and PANC1 cells were tran-
siently transfected with CUX1-specific or nonsilencing control siRNA. GRIA3 mRNA levels quantified by quantitative RT-PCR were nor-
malized to RPLP0 as housekeeping gene and expressed relative to control cells. *P < .05. Results expressed as mean ± SEM are
representative of three independent experiments. (B) Transient CUX1 overexpression increases GRIA3 mRNA. PANC1 cells were tran-
siently transfected with the C-terminal CUX1 expression plasmid or an empty vector. GRIA3 mRNA levels were quantified by quantitative
RT-PCR, normalized to RPLP0, and expressed relative to control cells. *P< .05. Results expressed as mean ± SEM are representative of
three independent experiments. (C) Knock-down of CUX1 decreases GRIA3 protein. PANC1 and PaTu-8988t cells were transfected with
CUX1 or control siRNA. GRIA3 protein levels were analyzed by Western blot; β -actin was used as a housekeeping gene. Results are
representative of three independent experiments. (D) Transient overexpression of CUX1 increases GRIA3 protein. PANC1 and PaTu-
8988t cells were transfected with CUX1 or an empty plasmid. GRIA3 and β-actin levels were analyzed by Western blot. Results are
representative of three independent experiments.
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Figure 2. GRIA3 enhances tumor cell proliferation. (A) Knock-down of GRIA3 by siRNA leads to decreased proliferation compared with
control-transfected cells as assessed by thymidine incorporation assays 48 hours after transfection. *P < .05. Results expressed as
mean ± SEM are representative of three independent experiments. (B) Cell cycle analysis by FACS of PANC1 cells transfected with
GRIA3 siRNA or control siRNA. Cell cycle distribution was determined after PI staining, and this was shown as a percentage of cells
in the G1, S, and G2/M phases. Results are representative of three independent experiments. (C) PANC1 and PaTu-8988t were transiently
cotransfected with GRIA3 or empty vector and LacZ plasmids. To selectively assess the number of transfected cells, fixed cells were
X-Gal–stained and counted. Results are shown as X-Gal–positive cells per visual field. Results are representative of three independent
experiments. *P < .05. (D) In vivo growth of PANC1 cells stably expressing GRIA3 or control plasmid (two clones each). Cells were
injected as subcutaneous xenografts in nu/nu mice (six tumors per clone). After establishment of measurable tumors (day 1), tumor
volume was measured during the next 32 days. Tumor growth is shown relative to day 1 and presented as mean ± SEM of 12 tumors
per group, derived from two clones each. *P < .05 compared with control clones.
Figure 3. GRIA3 enhances tumor cell migration. (A) PANC1 cells transfected with GRIA3 or control siRNA were seeded onto Boyden
chamber inserts. Cells that migrated through the 8-μm pores were quantified after 6 hours using CellTiter-Glo viability assays. (B) PANC1
cells stably overexpressing GRIA3 or empty vector (two clones each) were seeded onto Boyden chamber inserts. Cells that migrated
through the pores were quantified after 6 hours using CellTiter-Glo viability assay. Results are shown as mean ± SEM after normalization
to proliferating cells in neighbor wells and are representative of three independent experiments. *P < .05.
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GRIA3 overexpression led to increased proliferation in two independent
clones compared with mock-transfected control clones (Figure W5).
These data indicate that GRIA3 stimulates tumor cell proliferation by
enhancing S-phase progression in vitro.
To confirm the effect of GRIA3 on tumor proliferation in vivo, we
performed experiments in nude mice analyzing subcutaneous xeno-
graft tumors of GRIA3 overexpressing PANC1 cells. GRIA3 over-
expression in two independent clones showed a significantly enhanced
tumor growth compared with mock-transfected clones (Figure 2D),
confirming a significant effect of GRIA3 on tumor growth in vivo.
GRIA3 Enhances Migration
Given the paramount role of GRIA3’s upstream regulator CUX1
on motility and invasion that we had described previously [10], we
investigated whether GRIA3 also affects tumor cell migration. There-
fore, we performed Boyden chamber migration experiments in PANC1
cells after knock-down or overexpression of GRIA3 by examining
migration through a porous membrane. We normalized for prolifera-
tion at the end of experiment to exclude a potential proliferation bias.
GRIA3 knock-down significantly reduced cell migration toward serum
as a chemotactic gradient (Figure 3A). Moreover, PANC1 clones stably
overexpressing GRIA3 were also assessed for migration differences. In
two independent clones, GRIA3 overexpression led to a significantly
enhanced migration compared with control clones (Figure 3B). This
indicates that, apart from its effects on proliferation, GRIA3 is also able
to promote tumor cell migration.
GRIA3 Protects from TRAIL- and Drug-Induced Apoptosis
In addition to the important role of CUX1 as a mediator of pro-
liferation and migration [10], we recently observed a pronounced ef-
fect of CUX1 on tumor cell survival and resistance to apoptosis [14].
Therefore, we investigated whether GRIA3 as CUX1 downstream
effector also affects resistance to apoptosis. We induced apoptosis by
TRAIL/TNFSF10. Knock-down of GRIA3 significantly enhanced
both basal and TRAIL-induced apoptosis in PANC1 and PaTu-8988t
cells, as determined by quantification of histone-associated DNA frag-
ments (Figure 4A). This was accompanied by activation of the effector
caspases-3 and -7 (Figure 4B) as well as enhanced PARP cleavage
(Figure 4C ) in both cell lines. In analogy, stable GRIA3 overexpression
protected from TRAIL-induced apoptosis (Figure 4D), indicating an
important role of GRIA3 in mediating resistance to apoptosis.
GRIA3 Protein Is Expressed in Pancreatic Cancer Tissues
On the basis of the high expression levels and functional relevance
of CUX1 for tumor progression in pancreatic cancer [10,14], we
sought to verify that the CUX1 target GRIA3 is expressed in pancre-
atic cancers by studying GRIA3 protein levels in a pilot series of 17
pancreatic adenocarcinomas. Unfortunately, the antibody available for
immunohistochemistry detects two subunits of the glutamate receptor
AMPAR, GRIA2 and GRIA3. Using this antibody, we detected strong
expression levels of GRIA2/3 in 13 of 17 examined pancreatic cancer
tissues (Figure 5A). Interestingly, a particularly strong staining was ob-
served in some tumor cells adjacent to neural structures (Figure 5B).
Agonists and Antagonists of Glutamate Receptors Modulate
Pancreatic Cancer Cell Survival
GRIA3 is a subunit of the AMPAR. AMPARs are heterotetrameric
complexes composed of combinations of four subunits, termed GRIA1-4.
Studies in the CNS revealed that AMPARs open on binding of ago-
nists such as glutamate and become permeable for ions such as cal-
cium, sodium, and potassium.
To assess whether GRIA3 is part of functional AMPARs in pancreatic
cancer, which might be therapeutically targeted by specific antagonists,
Figure 4. GRIA3mediates resistance toTRAIL-inducedapoptosis. (A–
C) PANC1 and PaTu-8988t cells were transfected with GRIA3 or con-
trol siRNA. About 36 hours later, TRAIL was added for 12 hours, and
apoptosis was quantified assessing histone-associated DNA frag-
ments (A), caspase-3/7 activity assays (B), and PARP cleavage using
Western blots (C). *P < .05. (D) PANC1 cells stably overexpressing
GRIA3 or empty vector (two clones each) were incubated with TRAIL
for 12 hours. Apoptosis was quantified to assess histone-associated
DNA fragments and shown asmean± SD at OD405-492. *P< .05. Re-
sults are representative of three independent experiments.
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we examined the expression levels of all four subunits in pancreatic
cancer cells. Quantitative RT-PCR demonstrated the expression of
GRIA1, 3, and 4 in both PANC1 and PaTu-8988t. Although expres-
sion levels were not quantitatively compared, GRIA2 seemed to be ex-
pressed less in both cell lines (Figure W6). Interestingly, CUX1 was
not able to significantly regulate mRNA expression of GRIAs other
than GRIA3, as assessed by quantitative RT-PCR (data not shown).
To demonstrate the functionality of glutamate receptors in pan-
creatic cancer cells, we incubated PANC1 and PaTu-8988t cells with
increasing concentrations of glutamate in glutamate-free medium. Ad-
dition of glutamate led to a significant increase in cell viability (Fig-
ure 5C ), suggesting the presence of functional glutamate receptors.
However, because we could not rule out that the observed effect
was due to glutamate depletion independently of the presence of func-
tional glutamate receptors, we wished to corroborate our observations
by using AMPAR inhibitors.
Several compounds have been described as inhibitors for AMPARs,
among them are the selective noncompetitive AMPAR antagonist
GYKI52466 and the noncompetitive allosteric AMPAR antagonist
SYM2206. On the basis of our findings that GRIA3 strongly affects
tumor cell survival, we aimed to investigate the effects of AMPAR antag-
onists as potential therapeutic modalities. We incubated both PANC1
and PaTu-8988t cells with increasing concentrations of GYKI52466
or SYM2206. Interestingly, both compounds dose-dependently inhib-
ited the viability of both cell lines, suggesting that therapeutic inter-
ference with glutamate receptor signaling by application of AMPAR
antagonists might represent a new treatment approach for pancreatic
cancer (Figure 5D).
Discussion
By applying a sequential approach of transcriptional profiling and loss-
of-function screening, we identified the AMPAR subunit GRIA3 as a
downstream target of the transcription factor CUX1 and as an impor-
tant mediator of its effects on tumor proliferation, survival, and migra-
tion in pancreatic cancer cells in vitro and in vivo. To our knowledge,
this is the first report of AMPAR expression and its functional impli-
cation in tumor progression of solid cancers outside the CNS.
We report that targeting AMPARs by specific inhibitors reduced
tumor cell growth, indicating that targeting AMPARs might repre-
sent a novel therapeutic approach in patients with pancreatic cancer.
Within the CNS, expression of GRIA3 and other glutamate recep-
tors has been reported in gliomas and neuroblastomas [20,21]. In gli-
omas, high expression levels of GRIA1 have been implicated in tumor
progression. De Groot et al. [20] described a statistically significant
increase in GRIA1 expression in high-grade glioblastoma samples com-
pared with that in low-grade tumors. In analogy to our findings on
GRIA3, knock-down of GRIA1 decreased glioma cell proliferation
and increased apoptosis in vitro and in xenografts in vivo [20]. Re-
cently, Piao et al. [22] showed that overexpression of GRIA1 increased
Figure 5. GRIA2/3 is expressed in pancreatic cancer, and glutamate receptor modulators affect pancreatic cancer cell viability. (A, B)
Immunohistochemistry of human pancreatic cancer tissues using an antibody directed against GRIA2/3. (A) Representative picture of a
GRIA2/3–positive ductal pancreatic carcinoma tissue. Bar, 100 μm. (B) GRIA2/3–positive pancreatic cancer cells adjacent to a neural
structure. Bar, 40 μm. (C) Effect of glutamate on the viability of PANC1 and PaTu-8988t cells. Cells were incubated in glutamate-free
medium with increasing concentrations of glutamate for 72 hours. Cell viability was determined using MTT assays. Results expressed as
mean ± SEM are representative of three independent experiments. *P < .05 compared with cells without glutamate addition. (D) Effect
of the glutamate receptor antagonists GYKI52466 (0-100 μM) and SYM2206 (0-100 μM) on cell viability of PANC1 and PaTu-8988t cells
after 72 hours of incubation as assessed by MTT assays. Results are representative of three independent experiments. *P < .05 com-
pared with untreated cells.
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glioma cell adhesion to extracellular matrix, leading to enhanced tumor
cell invasion.
The intracellular signaling events downstream GRIA3 in tumor
cells remain to be elucidated. In postsynaptic neurons, stimulation
of AMPARs with agonists such as glutamate or AMPA leads to the
opening of an ion channel and subsequent influx of cations such as
calcium, sodium, and potassium. In the cell lines used, we were un-
able to show a significant increase in intracellular calcium content
after glutamate or AMPA stimulation, as determined by FURA- and
aequorin-based calcium measurements (Griesmann et al., unpublished
observations). This suggests that GRIA3 signaling occurs calcium-
independently. Furthermore, the main source of glutamate in the tu-
mor environment remains unclear to date. GRIA-positive tumor cells
may be stimulated by glutamate in the serum, which is known to con-
tain significant amounts of glutamate [23]. In addition, it can by hy-
pothesized that cancer cells are able to metabolize glutamine into
glutamate by glutaminase, a process well described in the CNS. Al-
ternatively, glutamate may also be produced by transamination of 2-
oxoglutarate, an intermediate in the citric acid cycle [24]. Moreover, a
constitutive activation of GRIA3 can also not be ruled out, and a de-
tailed functional characterization of stimulation and downstream sig-
naling of AMPARs in cancer cells is warranted.
Likewise, the upstream regulation of GRIA3 expression by onco-
genic signaling cascades requires further studies. We show that GRIA3
is regulated on mRNA and protein levels by the homeodomain tran-
scription factor CUX1. To our knowledge, the promoter of GRIA3 has
not been characterized in detail. On the basis of our functional data,
we speculate that GRIA3 expression might be modulated by several
tumor-promoting signaling events, among them is the CUX1-induced
signaling pathway. A characterization of the GRIA3 promoter includ-
ing a detailed mapping of CUX1 binding sites is warranted to prove
that GRIA3 is a direct target of CUX1.
Outside the CNS, only few data exist on the expression and func-
tion of AMPARs. Ganor et al. [25] found that human T cells express
GRIA3 and observed that glutamate triggers integrin-mediated adhe-
sion as well as chemotactic migration. The same group extended their
studies examining T-cell leukemias and cutaneous T-cell lymphomas
[26]. They found high GRIA3 levels in both malignancies and dem-
onstrated that glutamate enhanced growth and spreading, facilitating
engraftment of T-cell leukemia cells in vivo and accompanied by in-
duction of EMMPRIN/CD147, a cancer-associated matrix metallo-
proteinase inducer [26]. The authors hypothesized that GRIA3 may
enhance spreading and engraftment of lymphoma cells in the nervous
system with high glutamate levels. In pancreatic cancer, we also ob-
served a significant effect of GRIA3 on cancer cell migration in vitro.
By analogy, it can be speculated that GRIA3 expression in pancreatic
cancer cells might stimulate the perineural invasion of the tumor,
which represents a typical growth pattern in pancreatic cancer. This
is in accordance to our observation of strong GRIA2/3 expression in
some tumor cell clusters adjacent to neural structures. Further studies
are warranted to correlate GRIA expression patterns in whole resected
specimens with histopathologic criteria such as perineural invasion to
verify this hypothesis.
On the basis of the high expression and the strong effects of GRIA3
on proliferation, survival, and migration, targeting GRIA3 might rep-
resent an interesting novel therapeutic approach for pancreatic cancer.
To date, no specific inhibitor for GRIA3 is available. Therefore, we
used inhibitors that have been shown to inhibit ionotropic AMPARs
containing the subunits GRIA1, 2, 3, or 4. Apart fromGRIA3,we could
confirm the expression of GRIA1 and GRIA4 mRNA in pancreatic
cancer cell lines. We observed a significant inhibitory effect on tumor
cell viability after incubation with two different AMPAR antagonists,
SYM2206 and GYKI52466. Our data are in accordance with previ-
ous reports on the cytotoxic effects of AMPA antagonists on various
tumor cell lines in vitro. Rzeski et al. [27] demonstrated strong anti-
proliferative and antimigratory effects of GYKI52466 on astrocy-
toma, breast, colon, and lung carcinoma cells. Recently, Stepulak
et al. [28] analyzed RNA expression patterns of the different mem-
bers of the glutamate receptor family in various cancer cell lines and
found RNA levels of AMPAR subunits including GRIA3 in several
non-CNS cancer cell lines. This indicates that targeting AMPARs
might represent a novel therapeutic avenue not only for pancreatic
cancer but also for a variety of tumors of different origin. Although
our data indicate an important role of GRIA3 in cancer progression,
we cannot rule out that other GRIA subunits that are targeted by
available AMPA inhibitors might also affect tumor cell survival. Be-
sides GRIA3, we detected expressions of GRIA1 and GRIA4 in pan-
creatic cancer cells. Interestingly, these subunits were not significantly
regulated by CUX1. Further studies are required to delineate the role
of the different GRIA subunits for cancer progression and to define
the most promising GRIA subunit as target of AMPA antagonists.
In summary, we identified GRIA3 as an important mediator of tu-
mor cell survival, proliferation, and migration and as a downstream
target of CUX1, which has been shown to orchestrate a complex tran-
scriptional program enhancing tumor progression [10,11]. Targeting
GRIA3 by specific inhibitors represents a promising novel target for
pancreatic cancer therapy.
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Table W1. List of the 41 Genes Analyzed in the RNAi Screen.
Gene Symbol Relative Viability
(siRNA Sequence 1)
Relative Viability
(siRNA Sequence 2)
Relative Viability
(siRNA Sequence 3)
Mean Viability
Relative to Control
Significance
Criteria
SIRT2 0.60 0.64 0.76 0.67 *
GJA1 0.77 0.65 0.59 0.67 *
GRIA3 0.71 0.57 0.88 0.72 *
PVRL3 0.68 0.57 0.97 0.74 *
CXCL12 0.45 0.95 0.42 0.61 *
FMOD 0.88 1.46 1.25 1.20 *
ARNTL 1.47 1.65 1.13 1.42 *
S100A10 0.80 0.43 0.89 0.71
LLT1 0.56 0.76 0.86 0.73
TFDP1 0.84 0.45 1.07 0.78
PDLIM1 0.87 0.78 0.72 0.79
SEMA3A 0.61 0.81 1.06 0.83
MMP3 0.82 0.90 0.82 0.85
ANK1 1.16 0.78 0.65 0.86
ETV4 1.01 0.66 0.93 0.87
HMGN1 1.11 0.85 0.65 0.87
ITGA5 0.55 0.97 1.09 0.87
COL4A1 0.73 0.88 1.09 0.90
SERPINA3 0.87 1.02 0.82 0.90
SLIT2 0.91 0.81 1.01 0.91
CDH2 1.10 0.69 1.01 0.93
CHI3L2 0.82 0.94 1.08 0.94
EFNA2 0.76 1.16 0.94 0.95
NRAS 1.17 0.67 1.01 0.95
CDH18 0.67 0.98 1.26 0.97
TM4SF1 0.66 0.98 1.30 0.98
ITGA6 0.82 1.26 0.86 0.98
COL3A1 0.68 0.86 1.42 0.99
RPS27 1.17 0.79 1.03 1.00
SAA1 0.95 1.20 0.87 1.00
CD34 1.12 1.22 0.75 1.03
MYBL1 1.41 0.67 1.02 1.03
DCK 1.13 1.13 0.84 1.03
LUM 0.77 1.05 1.28 1.03
GSTZ1 0.95 1.13 1.10 1.06
DAB2 0.69 0.95 1.65 1.10
LGALS9 0.96 1.20 1.14 1.10
IL1A 1.01 1.08 1.22 1.10
EPHA1 0.69 1.21 1.44 1.11
ALCAM 1.31 0.99 1.07 1.12
PTN 1.04 1.46 1.18 1.23
Cell viability relative to the mean viability of 11 nonsilencing control sequences, as determined by CellTiter-Glo assays, is shown as mean and separately for silencing sequences 1 to 3. The genes used for
the screen were previously identified as regulated by CUX1 in a microarray approach [10]. Changes in cell viability greater than 25% after knock-down of a particular gene in two of three silencing
sequences were considered as significant, and these are marked with an asterisk.
Figure W1. Knock-down efficiency of five randomly selected
genes from the RNAi library as assessed by quantitative RT-PCR
in HT1080 cells, normalized to RPLP0 expression as the house-
keeping gene. Results are expressed as mean ± SEM and are rep-
resentative of three independent experiments.
Figure W2. mRNA expression, as quantified by quantitative RT-
PCR, of the seven screen hits in PANC1 cells transiently trans-
fected with siRNA against CUX1 (siCUX) or nonsilencing control
siRNA. Results are shown as mean ± SEM normalized to RPLP0
expression as the housekeeping gene. Results are representative
of three independent experiments.
Figure W4. (A) Stable overexpression of CUX1 increases GRIA3 protein. PANC1 cells were stably transfected with the transcriptionally
active CUX1 expression plasmid. GRIA3 protein levels were analyzed in two different clones with different CUX1 expression levels by
Western blot using specific antibodies; β -actin was determined as the housekeeping gene. (B) Stable overexpression of CUX1 increases
GRIA3 mRNA. PANC1 clones 1 and 2 stably expressing two different levels of the transcriptionally active CUX1 expression plasmid
(shown in panel A) were analyzed for GRIA3 mRNA by quantitative RT-PCR, normalized to RPLP0 expression as the housekeeping gene,
and expressed relative to clone 1. *P < .05 compared with clone 1. Results are expressed as mean ± SEM and are representative of
three independent experiments.
Figure W3. mRNA expression, as quantified by quantitative RT-
PCR, of seven screen hits in PaTu-8988t cells transiently trans-
fected with siRNA against CUX1 (siCUX) or nonsilencing control
siRNA. Results are shown as mean ± SEM normalized to RPLP0
expression as the housekeeping gene. Results are representative
of three independent experiments.
Figure W5. PANC1 cells stably expressing GRIA3 or control plas-
mid (two clones each) were assessed for differences in prolifera-
tion by using BrdU proliferation assays 24 hours after seeding.
Results were normalized to control clone 1; these are shown as
mean ± SEM and are representative of three independent experi-
ments. GRIA3 expression level and β -actin as the housekeeping
gene, as determined by Western blot, are shown below.
Figure W6. Expression of hGRIA1-4 in PANC1 and PaTu-8988t cells,
as assessed by quantitative RT-PCR normalized toRPLP0 expression
as the housekeeping gene. Results are expressed as mean ± SEM
and are representative of three independent experiments.
